title: Anticancer Drug Combinations, How Far We can Go Through?
abstract: Many clinical cancer therapies are less effective by using one anticancer drug only due to refractory properties of cancer pathogenesis and drug resistance property in advanced cancer patients. A general consensus among clinicians is that anticancer drug cocktail might better control cancer progresses and metastasis than single drug therapeutics in clinical trials. Despite great popularity, the anticancer drug combination dogma has not been established. The complexity of drug combination dogma discovery is more than we can expect now. This article speculates possible routes we can undertake in this matter. The background knowledge of drug combination therapy presently practiced and possible future landscapes and drawbacks of cancer drug combinative therapies are highlighted.
authors.affiliation: School of Life Sciences, Shanghai University, Shanghai200444, PR China.
authors.forename: Da-Yong
authors.initials: DY
authors.lastname: Lu
authors.forename: En-Hong
authors.initials: EH
authors.lastname: Chen
authors.forename: Hong-Ying
authors.initials: HY
authors.lastname: Wu
authors.forename: Ting-Ren
authors.initials: TR
authors.lastname: Lu
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.forename: Jian
authors.initials: J
authors.lastname: Ding
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D057285:Precision Medicine / Q000379:methods
chemical_list: D000970:Antineoplastic Agents